Type of antibody:
Recombinant antibodies
recombinant human IgG1

Specifications for CD42a antibodies


Clone REA209 recognizes CD42a, a 22 KDa transmembrane glycoprotein, which is also known as glycoprotein IX (GPIX). CD42a is a single-pass type I membrane protein with leucine rich motif containing a series of tandem repeats of a 24-amino acid sequence flanked by conserved disulfide loops, in its ligand binding domains. Expression of CD42a is found on platelets and megakaryocytes. CD42a, together with GPIb receptor complex and platelet glycoprotein V forms a complex which serves as the receptor for von Willebrand factor (VWF). The interaction of the GPIb-IX-V complex to VWF initiates initial platelet adhesion to vascular subendothelium after vascular injury, platelet activation, thrombosis, and hemostasis. Other known ligands for GPIb–IX–V include α-thrombin, clotting factors XI/XIIa, and high-molecular weight kininogen.
Additional information: Clone REA209 displays negligible binding to Fc receptors.


Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD42a may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Detailed product information

Technical specifications

Isotyperecombinant human IgG1
Type of antibodyRecombinant antibodies
Molecular mass of antigen [kDa]22
Distribution of antigenmegakaryocytes, platelets

Resources for CD42a antibodies


Please follow this
to download the Certificate of Conformity (CoC) by lot number.

References for CD42a antibodies


  1. Shrimpton, C. N. et al. (2002) Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J. Exp. Med. 196: 1057
  2. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  3. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  4. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  5. Andrews, R. K. et al. (1997) Molecular mechanisms of platelet adhesion and activation. Int. J. Biochem. Cell Biol. 29(1): 91-105
  6. Andrews, R. K. et al. (2003) Glycoprotein Ib-IX-V. Int. J. Biochem. Cell Biol. 35(8): 1170-1174
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  8. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition

Seems like you are coming from USA!
Do you want to visit our website in your country?